Explore the words cloud of the ABLAVIEW project. It provides you a very rough idea of what is the project "ABLAVIEW" about.
The following table provides information about the project.
|Coordinator Country||Spain [ES]|
|Total cost||3˙524˙880 €|
|EC max contribution||2˙467˙416 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-05-01 to 2022-04-30|
Take a look of project's partnership.
|1||MEDLUMICS SL||ES (TRES CANTOS MADRID)||coordinator||2˙467˙416.00|
Medlumics innovation, AblaView™ is an optically guided radiofrequency (RF) ablation catheter to treat atrial fibrillation and arrhythmias. The AblaView™ technology is based on Optical Coherence Reflectometry) which in turn allows the Electrophysiologist to view the ablation of precise areas of the myocardial tissue “inside the heart in real time” for the treatment of Atrial fibrillation.
Atrial Fibrilation is the most common type of heart arrhythmia. An estimated 33.5 million people worldwide suffered from AF and prevalence of the disease is expected to increase as the number of people over the age of 65 continues to expand. There were 491.000 catheter-based procedures carried out worldwide in 2015. AblaView is a first-in-class optically guided radio-frequency ablation system to provide missing information about the local catheter environment and directly assess lesion progress in real time by probing the tissue surrounding the ablation electrode. The key disruptive nature of MedLumics’ AblaView™ technology is both been able to precisely control and visualize in real-time tissue ablation at the desired sites of AF propagation but without over-treatment or indeed ablation of “healthy” tissue. The current technologies do not allow for this level of control or visualization and consequently expose the AF patient to inappropriate ablations and serious side effects or adverse events.
MedLumics’ technology addresses exactly that problem with its AblaView catheter: it will provide the clinicians with direct, real-time information on lesion formation in the tissue surrounding the catheter’s radiofrequency electrode during the ablation process. Although AF patients are expected to benefit most from this innovation, AblaView is also expected to improve the accuracy of other arrhythmia ablation procedures.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ABLAVIEW" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ABLAVIEW" are provided by the European Opendata Portal: CORDIS opendata.